Clinical trial NCT06981754: Dexamethasone Palmitate for PONV After Minimally Invasive Endoscopic Surgery
Official title: Intravenous Dexamethasone Palmitate for Prophylaxis of Postoperative Nausea and Vomiting After Minimally Invasive Endoscopic Surgery
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Postoperative Nausea and Vomiting
Dexamethasone Palmitate
Minimally Invasive Endoscopic Procedures
Lead sponsor: Beijing Tiantan Hospital
Sponsor class: OTHER
First posted: 2025-05-21
Enrollment: 588
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Dexamethasone is almost one of the most commonly used drugs for postoperative nausea and vomiting (PONV) prevention. However, PONV is still a complex problem to be solved; for example, even with preoperative dexamethasone administration, 14.0-26.3% of patients undergoing minimally invasive endoscopic procedures still experience PONV within 24 hours postoperatively. Compared to dexamethasone, dexamethasone palmitate has a long-lasting anti-inflammatory effect, 2-5 times that of traditional water-soluble dexamethasone, with fewer adverse effects. This trial aims to assess the effect and safety of preoperative dexamethasone palmitate on PONV after surgery.


Eligibility criteria: Inclusion Criteria:

* Aged 18 to 65 years;
* Providing written informed consent;
* Perform elective minimally invasive endoscopic surgery (laparoscopic surgery, thoracoscopic surgery) undergoing general anesthesia.

Exclusion Criteria:

* Known to be allergic to dexamethasone;
* Any systemic glucocorticoids within 3 months before trial entry;
* History of severe heart disease, liver/kidney failure, or systemic rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, et al);
* Cognitive impairment or severe mental illness;
* Uncontrolled diabetes or infectious diseases;
* Pregnancy or breastfeeding.

Primary outcomes:
measure: The incidence of PONV
timeFrame: Within the first 24 hours postoperatively
Secondary outcomes:
measure: The Incidence of PONV
timeFrame: At 6 hours, 48 hours, and 72 hours postoperatively
measure: Incidence of postoperative nausea (PON) and postoperative vomiting (POV)
timeFrame: At 6 hours, 24 hours, 48 hours, and 72 hours postoperatively
measure: The number of vomiting or retching episodes
timeFrame: Within 6 hours, 24 hours, 48 hours, and 72 hours postoperatively
measure: The severity of PONV
timeFrame: At 6 hours, 24 hours, 48 hours, and 72 hours postoperatively
measure: Participant satisfaction with PONV management
timeFrame: At 6 hours, 24 hours, 48 hours, and 72 hours postoperatively
measure: The use of rescue antiemetic drugs
timeFrame: During the 0-24 hours, 24-48 hours, and 48-72 hours postoperatively
measure: The quality of postoperative recovery (QoR)
timeFrame: At 24 and 48 hours postoperatively, discharge, and 1 month postoperatively
measure: The VAS scale
timeFrame: At 6 hours, 24 hours, 48 hours, and 72 hours postoperatively
measure: Postoperative length of stay (LOS)
timeFrame: At discharge
measure: Safety outcomes
timeFrame: Throughout the entire research period
Other outcomes:
Locations:
Study officials:
References:
citation: Apfel CC, Laara E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999 Sep;91(3):693-700. doi: 10.1097/00000542-199909000-00022.
citation: Gan TJ, Belani KG, Bergese S, Chung F, Diemunsch P, Habib AS, Jin Z, Kovac AL, Meyer TA, Urman RD, Apfel CC, Ayad S, Beagley L, Candiotti K, Englesakis M, Hedrick TL, Kranke P, Lee S, Lipman D, Minkowitz HS, Morton J, Philip BK. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. Anesth Analg. 2020 Aug;131(2):411-448. doi: 10.1213/ANE.0000000000004833.
citation: Gan TJ. Risk factors for postoperative nausea and vomiting. Anesth Analg. 2006 Jun;102(6):1884-98. doi: 10.1213/01.ANE.0000219597.16143.4D.
citation: Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, Watcha M, Chung F, Angus S, Apfel CC, Bergese SD, Candiotti KA, Chan MT, Davis PJ, Hooper VD, Lagoo-Deenadayalan S, Myles P, Nezat G, Philip BK, Tramer MR; Society for Ambulatory Anesthesia. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014 Jan;118(1):85-113. doi: 10.1213/ANE.0000000000000002.
citation: Hahm TS, Ko JS, Choi SJ, Gwak MS. Comparison of the prophylactic anti-emetic efficacy of ramosetron and ondansetron in patients at high-risk for postoperative nausea and vomiting after total knee replacement. Anaesthesia. 2010 May;65(5):500-4. doi: 10.1111/j.1365-2044.2010.06310.x. Epub 2010 Mar 19.
citation: Habib AS, Chen YT, Taguchi A, Hu XH, Gan TJ. Postoperative nausea and vomiting following inpatient surgeries in a teaching hospital: a retrospective database analysis. Curr Med Res Opin. 2006 Jun;22(6):1093-9. doi: 10.1185/030079906X104830.
citation: DREAMS Trial Collaborators and West Midlands Research Collaborative. Dexamethasone versus standard treatment for postoperative nausea and vomiting in gastrointestinal surgery: randomised controlled trial (DREAMS Trial). BMJ. 2017 Apr 18;357:j1455. doi: 10.1136/bmj.j1455.
citation: Feo CV, Sortini D, Ragazzi R, De Palma M, Liboni A. Randomized clinical trial of the effect of preoperative dexamethasone on nausea and vomiting after laparoscopic cholecystectomy. Br J Surg. 2006 Mar;93(3):295-9. doi: 10.1002/bjs.5252.
citation: Rwei AY, Sherburne RT, Zurakowski D, Wang B, Kohane DS. Prolonged Duration Local Anesthesia Using Liposomal Bupivacaine Combined With Liposomal Dexamethasone and Dexmedetomidine. Anesth Analg. 2018 Apr;126(4):1170-1175. doi: 10.1213/ANE.0000000000002719.